[HCS PHARMA] We wish you a Merry Christmas and a Happy New Year!
December 2018
Few days before 2019 we are happy to announce that BIOMIMESYS® Brain hydroscaffold for neuronal cells will be available next month. We present preliminary results below. Of course, you can already use other BIOMIMESYS® hydroscaffolds for your assays and you can even create your own personalized BIOMIMESYS®! Just contact us!Merry Christmas and Happy New Year!
Quelques jours avant 2019 nous sommes heureux de vous annoncer que BIOMIMESYS® Brain hydroscaffold pour cellules neuronalessera disponible le mois prochain. Nous présentons des résultats préliminaires ci-dessous. Bien sur, vous pouvez déjà utiliser les autres BIOMIMESYS® hydroscaffolds pour vos essais et il est même possible de créer votre propre BIOMIMESYS® hydroscaffold personnalisé. Contactez-nous !Joyeux Noel et Bonne année !
Mathematical modeling of spheroid formation in BIOMIMESYS
In this article, researchers from Sorbonne University (Paris, France) proposed an explanation for the patterns followed by breast cancer cells when seeded in BIOMIMESYS, i.e. spherical aggregates.
Poster – Characterisation of 3D cultured primary human hepatocytes and HepaRG for DMSO-free preclinical toxicity testing
Hepatocytes in primary cultures are still the gold standard in the pharmaceutical industry ; however they are expensive and have a very short lifespan with a progressive loss of specific functions over time. The dipolar aprotic solvent, dimethyl sulfoxide (DMSO) is wildly used to stabilize the liver specific function of human hepatocytes in vitro. It is also used to potentialize the differentiation of the human HepaRG-hepatocytes-like cells that share functional characteristics with human hepatocytes. Besides its free radicals scavenging properties that contribute to hepatoprotection, DMSO has been shown to interfere with apoptosis signalling pathways. To avoid this disadvantage, we have analysed the functional properties of freshly isolated human hepatocytes (FIH) and HepaRG-hepatocyte-like cells in 3D cultures performed using Ultra Low Attachment Technology (ULA) plates.
Feedback from BioFit Lille 2018!
HCS Pharma team enjoyed attending BioFit 2018 and hosted events in Lille last week! Our business developer Nathalie had many fruitful BtoB meetings along the convention, and our study director Elodie could meet lots of people interested in our imaging technology and BIOMIMESYS products while on HCS pharma booth (D4/2) within Lille Northern France Biocluster.
How automation will transform the lab of the future
Over the last few years, scientists have discovered connections between gut microbiota imbalances and various diseases. Now, in a study using mice, biologists from the CNRS, INSERM, and Claude Bernard Lyon 1 University—together with colleagues from the Institut Pasteur de Lille and the NIH (USA)—have revealed a surprising relationship between a viral detection system, the composition of the gut microbiota, and the development of skin allergies. Their findings, published in PNAS (September 24, 2018) suggest potential new therapies.
Feedback from HCS Pharma @ HI Europe Frankfurt 2018!
Our study directors Elodie and Pierre-Jean enjoyed the last edition of Health Ingredients Europe, which took place in Frankfurt (Germany) from the 27th to the 28th of November 2018.
Few days before 2019 we are happy to announce that BIOMIMESYS® Brain hydroscaffold for neuronal cells will be available next month. We present 
Quelques jours avant 2019 nous sommes heureux de vous annoncer que BIOMIMESYS® Brain hydroscaffold pour cellules neuronales sera disponible le mois prochain. Nous présentons des résultats préliminaires ci-dessous. Bien sur, vous pouvez déjà utiliser les autres 
